Phase 3 trials are large, confirmatory studies that provide the main evidence regulators use to decide on market approval for a drug or device. Since AI tools may predict or simulate phase 3 outcomes based on earlier‑phase data, non‑technical leaders need a firm grasp of what this phase entails and the high consequences of inaccurate predictions.